EMCURE PHARMA
Ahead of Market: 10 things that will decide stock market action on Monday
Sensex and Nifty ended lower during Muhurat Trading on November 8, snapping a six-session winning streak. Nifty slipped below 25,000 as investors booked profits. However, broader market sentiment remained positive, with 2,716 NSE stocks advancing against 736 declines.
PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horses
HDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 2083. He favours largecaps for valuation comfort, highlights selective stock opportunities and urges investors to prioritise earnings visibility and disciplined asset allocation.
Ahead of Market: 10 things that will decide stock market action on Friday
Indian markets staged a powerful rally, with Sensex jumping 2,009 points and Nifty gaining 576 points. Improved global sentiment, easing crude prices, US midterm election results, foreign investor buying and strong Q2 earnings lifted market capitalisation above Rs 500 lakh crore.
Ahead of Market: 10 things that will decide stock market action on Thursday
Indian markets extended their rally, with Sensex gaining 384 points to 77,301 and Nifty rising 150 points to 23,961, marking two-month highs. Positive sentiment, strong earnings, festive demand and buying across mid- and small-caps supported gains.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 crore
Emcure Pharmaceuticals Ltd has posted a remarkable consolidated net profit of Rs 325.06 crore for the September quarter, reflecting substantial growth. Revenue surged from Rs 2,269.82 crore to Rs 2,820.47 crore during this period, with international operations increasing by 34 per cent. Additionally, domestic revenue witnessed an 11.1 per cent rise, as company leaders expressed confidence in sustaining this positive trend through the latter half of FY27.
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore
Emcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore. Revenue grew 24.3%, while EBITDA rose 30.9%, supported by strong international business growth.
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Indian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC faced a decline in consolidated net profit, impacted by the cigarette business, despite revenue growth. Marico saw a significant rise in net profit and expanding EBITDA margins during the quarter. Container Corporation of India reported a subdued performance with a slight decline in net profit compared to last year.
D-Street in gloomy mood, but Kotak sees 3 triggers for rebounds and adds 5 midcap stocks to portfolio
Dalal Street faces significant market challenges, leading Kotak Institutional Equities to spotlight selective stock value. With large-cap stocks in view, the impact of geopolitical strife and fluctuating crude oil prices weighs heavily on investor sentiment. The brokerage sees potential recovery catalysts in peace talks regarding the Iran-US situation and favorable Q2 earnings.
AMFI reshuffle: NSE may get largecap status, SBI Fund Management may become midcap in H1 CY27
Nuvama expects NSE to enter the largecap category and SBI Funds Management to become a midcap in AMFI’s H1 CY27 reshuffle. Bosch, Siemens Energy India and others may be upgraded, while several largecaps could move down. The revised classification will take effect from February 1, 2027, after H2 CY26 market-cap rankings.
Emcure Pharma shares in focus after GST Department conducts search at Mumbai offices
Emcure Pharmaceuticals' shares could see action following a Goods and Services Tax search at its Mumbai offices. The inspection concluded this week. The company recently reported a robust rise in revenue and profit after tax. Domestic and international businesses both showed strong performance.
Emcure Pharma Q2 profit rises 25%, revenue up 13% on broad-based growth
Pune-based Emcure Pharmaceuticals reported a 13.4% year-on-year rise in consolidated revenue to ₹2,270 crore in the September quarter, supported by double-digit growth in both domestic and international markets. Net profit increased 24.7% YoY to ₹251 crore, while EBITDA rose 15.2% to ₹439 crore, with a margin of 19.3%, the company said on Tuesday.
Stocks in news: TCS, Akzo Nobel, Indosolar, Emcure Pharma, Enviro Infra
Markets experienced volatility within a tight range, closing slightly lower, continuing the consolidation trend. TCS is set to release its Q1 earnings, projecting a modest net profit increase. Asian Paints divested a 4.42% stake in Akzo Nobel, while ICICI Prudential MF acquired shares. Additionally, Emcure Pharma's Ahmedabad facility passed a US FDA inspection without any observations.
Emcure Pharma shares in focus as Bain Capital likely to offload 2.4% stake via block deal
BC Investments IV, linked to Bain Capital, is expected to sell a 2.4% stake in Emcure Pharmaceuticals. The sale will occur through a block deal valued at Rs 551 crore. About 45.5 lakh shares will be sold at Rs 1,279.80 each. Kotak Securities is managing the deal. Emcure's stock is currently below its all-time high despite strong quarterly results.
Emcure Pharma shares advance 10% as Kotak Equities sees 28% upside in stock
Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal challenges, Emcure is projected to achieve a 13% overall sales CAGR between FY2024 and FY2027. Enhanced productivity following a 20%+ expansion in field force since FY2022, along with increased utilisation of new facilities, is expected to contribute to robust EBITDA and EPS CAGRs of 18% and 29%, respectively, during the same period.
Emcure Pharma shares jump over 4% post listing. Should you buy, sell or hold?
Pune-based Emcure Pharmaceuticals listed at Rs 1,325, a 31.4% premium on Rs 1,008 IPO price. QIBs subscribed 195.8 times, non-institutional investors 48.3 times. Analysts recommend long-term holding. IPO proceeds target debt and corporate purposes. Offering products in therapeutic areas, Emcure recorded Rs 6,658 crore revenue in FY24 and operates in Europe, Canada.
Emcure Pharma shares debut with 31% premium over issue price
Before listing, the company's shares traded at a Rs 360 premium in the grey market. It raised Rs 582 crore from anchor investors, including HDFC MF, ICICI Pru MF, SBI MF, Abu Dhabi Investment Authority, Goldman Sachs Asset Management, Nomura, and HDFC Life. Analysts are bullish on the IPO for listing gains and long-term growth, citing its strong position in domestic therapeutics and expansion plans in India and exports.
Namita Thapar-backed Emcure Pharma IPO opens for subscription. Should you bid?
Emcure Pharma IPO: Emcure Pharmaceuticals IPO, with marquee investors like Goldman Sachs, offers a fresh equity issuance and OFS. Namita Thapar to earn Rs 127 crore through the stake sale. The company targets debt repayment and global expansion.
Shark tank fame Namita Thapar to rake in Rs 127 crore through Emcure Pharma IPO
Shark Tank's Namita Thapar, who is part of Emcure Pharmaceuticals' promoter group, is set to earn approximately Rs 127 crore through the upcoming IPO. Thapar, who acquired shares in Emcure at an average price of Rs 3.44 each, will sell around 12.68 lakh shares through the OFS component of the IPO. With the upper price band set at Rs 1,008 per share, the stake sale is expected to yield about Rs 127 crore.
Load More
